Status:
WITHDRAWN
Pain Assessment and Quality of Life in Back Pain Patients: Role of Milnacipran
Lead Sponsor:
Brigham and Women's Hospital
Collaborating Sponsors:
Forest Laboratories
Conditions:
Back Pain
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
1. To show that patients with greater pain sensitivity will show greater improvement in their symptoms (self-reported pain intensity, mood, sleep, and quality of life) than those with lower pain sensi...
Detailed Description
Chronic pain is a costly syndrome that influences every aspect of a patient's life. Significant interference with sleep, employment, social functioning, and daily activities is common. Chronic pain pa...
Eligibility Criteria
Inclusion
- 18 years or older
- Primary diagnosis of spinal pain for at least 6 months' duration
- Average pain intensity score of 4 or greater
Exclusion
- Current diagnosis of cancer or malignant disease
- Acute bone disease
- History of DSM-IV psychotic disorder
- Pregnancy
- Any illness judged by the PI to interfere with treatment
- Any acute condition requiring surgery
- Currently taking SNRI or MAOI
Key Trial Info
Start Date :
August 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2011
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT01221740
Start Date
August 1 2010
End Date
August 1 2011
Last Update
January 12 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Brigham and Women's Hospital Pain Trials Center
Chestnut Hill, Massachusetts, United States, 02467